FeesSafety
Pluang+

Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Market News
21 Nov 2026, 07:15 WIB
Reuben Gregg Brewer
View Source
Bullish
Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Bristol Myers Squibb, a major pharmaceutical company, currently offers a 4.3% dividend yield and trades at a price-to-earnings ratio well below the industry average. Its newer drug portfolio generated nearly $7.7 billion in revenue last quarter, growing 12% year-over-year, showing strong development success. However, the company faces a significant risk as its top-selling drug Eliquis will face generic competition starting in 2028, potentially reducing revenues sharply. Despite this, the company’s history of managing patent expirations and steady dividend increases suggests it remains a compelling investment for most investors willing to accept some uncertainty.

Bristol Myers Squibb shares are priced at USD 58.68 on Pluang as of Nov 21, 2026 07:41 WIB, showing a modest 0.58% gain in the last day. The stock offers a dividend yield of 4.32%, aligning closely with the article's mention of a 4.3% yield. With a market cap of $119.25 billion, the company remains a significant player in the health sector on Pluang.

More News (BMY)

Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Erasca has been upgraded from Hold to Buy following promising early trial results for its drug ERAS-0015, which showed unconfirmed response rates of 50% in pancreatic cancer and 64% in lung cancer. The company plans three registrational trials by 202...

Analyst Insights
Bullish
14 hours ago
Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb increased its full-year 2026 earnings guidance following a 12% revenue growth in its growth portfolio to $7.7 billion, driven by eight medicines each generating over $1 billion annually. The company is offsetting losses from pate...

Company Fundamentals
Bullish
2 days ago
Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Bristol-Myers Squibb reported a 12% revenue increase in its growth portfolio to $7.7 billion for Q3 2026, driven by eight medicines each generating over $1 billion annually. The company advanced four late-stage clinical trials, including FDA clearanc...

Company Fundamentals
Bullish
2 days ago
Erasca and Bristol Myers Squibb partner to test ERAS-0015 with navlimetostat in pancreatic cancer trial

Erasca and Bristol Myers Squibb partner to test ERAS-0015 with navlimetostat in pancreatic cancer trial

Erasca, Inc. has entered a clinical collaboration with Bristol Myers Squibb to evaluate the combination of Erasca's ERAS-0015, a pan-RAS molecular glue, with BMS's investigational PRMT5 inhibitor navlimetostat in a Phase 1/2 trial targeting MTAP-dele...

Market News
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App